TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Atara Biotherapeutics ( (ATRA) ) has issued an update.
On September 2, 2025, Atara Biotherapeutics announced a strategic reduction in its Board of Directors from ten to seven members to better align with its current operations and the boards of similar-sized public companies. This decision led to the voluntary resignation of directors Ameet Mallik, Pascal Touchon, and Maria Grazia Roncarolo, M.D., with Gregory A. Ciongoli being appointed as the new Chair of the Board, replacing Pascal Touchon.
The most recent analyst rating on (ATRA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
Atara Biotherapeutics’ overall stock score reflects significant financial challenges, with negative equity and cash flow issues being major concerns. However, technical indicators show some positive momentum, and recent corporate events suggest potential future growth opportunities. The valuation remains a cautionary factor due to current financial instability.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a Delaware-based company operating in the biotherapeutics industry, focusing on developing transformative therapies for patients with serious diseases.
Average Trading Volume: 53,637
Technical Sentiment Signal: Hold
Current Market Cap: $86.66M
See more data about ATRA stock on TipRanks’ Stock Analysis page.